An allergen-polymeric nanoaggregate as a new tool for allergy vaccination.
A recombinant hybrid composed of the two major allergens of the Parietaria pollen Par j 1 and Par j 2 has been generated by DNA recombinant technology (PjED). This hybrid was produced in E. coli at high levels of purity. Then, the engineered derivative has been combined with a synthetic polyaminoacidic derivative having a poly(hydroxyethyl)aspartamide (PHEA) backbone and bearing both butyryl groups (C4) and succinyl (S) moieties in the side chain (PHEA-C4-S). The allergen-copolymer nanoaggregate was characterized by means of DLS, zeta potential, electrophoretic mobility and atom force microscopy analysis displaying the formation of a stable complex. Its safety has been proved in vitro on a murine cell line, human erythrocytes and basophils. Moreover, the formation of the complex did not alter the ability of the allergens to cross-link surface bound specific IgE demonstrating that the combination of an engineered hybrid with a copolymer did not interfere with its biological activity suggesting its employment as potential vaccine against Parietaria-induced allergies.
Dipartimento di Scienze e Tecnologie Biologiche, Chimiche e Farmaceutiche (STEBICEF), Università degli Studi di Palermo, Via Archirafi 32, 90123 Palermo, Italy.
Mariano
M
Licciardi
Istituto di Biomedicina ed Immunologia Molecolare (IBIM), CNR, Via Ugo La Malfa, 153, Palermo, Italy.
Giovanna
G
Montana
Istituto per lo Studio dei Materiali Nanostrutturati (ISMN), CNR, Via Ugo La Malfa, 153, 90146 Palermo, Italy.
Maria Luisa
ML
Bondì
Istituto di Biomedicina ed Immunologia Molecolare (IBIM), CNR, Via Ugo La Malfa, 153, Palermo, Italy.
Angela
A
Bonura
Dipartimento di Scienze e Tecnologie Biologiche, Chimiche e Farmaceutiche (STEBICEF), Università degli Studi di Palermo, Via Archirafi 32, 90123 Palermo, Italy.
Cinzia
C
Scialabba
Istituto di Biomedicina ed Immunologia Molecolare (IBIM), CNR, Via Ugo La Malfa, 153, Palermo, Italy.
Mario
M
Melis
Dipartimento di Scienze e Tecnologie Biologiche, Chimiche e Farmaceutiche (STEBICEF), Università degli Studi di Palermo, Via Archirafi 32, 90123 Palermo, Italy.
Calogero
C
Fiorica
Dipartimento di Scienze e Tecnologie Biologiche, Chimiche e Farmaceutiche (STEBICEF), Università degli Studi di Palermo, Via Archirafi 32, 90123 Palermo, Italy.
Gaetano
G
Giammona
Istituto di Biomedicina ed Immunologia Molecolare (IBIM), CNR, Via Ugo La Malfa, 153, Palermo, Italy. Electronic address: paolo.colombo@ibim.cnr.it.
Paolo
P
Colombo
D000485:Allergens / Q000737:chemistry / Q000276:immunology* / Q000633:toxicity; D000818:Animals; D052179:Antigens, Plant / Q000737:chemistry / Q000276:immunology* / Q000633:toxicity; D001491:Basophils / Q000187:drug effects / Q000276:immunology; D002460:Cell Line; D002470:Cell Survival / Q000187:drug effects; D002626:Chemistry, Pharmaceutical; D004337:Drug Carriers; D004355:Drug Stability; D004586:Electrophoresis; D006461:Hemolysis / Q000187:drug effects; D006801:Humans; D006967:Hypersensitivity / Q000276:immunology / Q000517:prevention & control*; D007073:Immunoglobulin E / Q000276:immunology; D008027:Light; D008264:Macrophages / Q000187:drug effects / Q000473:pathology; D051379:Mice; D018625:Microscopy, Atomic Force; D053758:Nanoparticles; D036103:Nanotechnology; D010455:Peptides / Q000737:chemistry*; D010940:Plant Proteins / Q000737:chemistry / Q000276:immunology* / Q000633:toxicity; D012542:Scattering, Radiation; D013678:Technology, Pharmaceutical / Q000379:methods; D014611:Vaccination; D014614:Vaccines, Synthetic / Q000737:chemistry / Q000276:immunology* / Q000633:toxicity
D000485:Allergens; D052179:Antigens, Plant; D004337:Drug Carriers; C105336:PMAI protein, Parietaria judaica; C103299:Par j 2.0101; D010455:Peptides; D010940:Plant Proteins; D014614:Vaccines, Synthetic; C008965:alpha,beta-poly((2-hydroxyethyl)-aspartamide); D007073:Immunoglobulin E
Allergy; PHEA; Parietaria pollen; Polymeric nanoaggregates; Recombinant allergens